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How the ER-associated degradation (ERAD)
machinery accurately identifies terminally mis-
folded proteins is poorly understood. For lumi-
nal ERAD substrates, this recognition depends
on their folding and glycosylation status as
well as on the conserved ER lectin Yos9p. Here
we show that Yos9p is part of a stable complex
that organizes key components of ERAD ma-
chinery on both sides of the ER membrane,
including the transmembrane ubiquitin ligase
Hrd1p. We further demonstrate that Yos9p, to-
gether with Kar2p and Hrd3p, forms a luminal
surveillance complex that both recruits nonna-
tive proteins to the core ERAD machinery and
assists a distinct sugar-dependent step neces-
sary to commit substrates for degradation.
When Hrd1p is uncoupled from the Yos9p sur-
veillance complex, degradation can occur inde-
pendently of the requirement for glycosylation.
Thus,Yos9p/Kar2p/Hrd3pactsasagatekeeper,
ensuring correct identification of terminally mis-
folded proteins by recruitingmisfolded forms to
theERADmachinery, contributing to the interro-
gation of substrate sugar status, and preventing
glycosylation-independent degradation.
INTRODUCTION
Proteins that traverse the secretory pathway fold in the
endoplasmic reticulum (ER). This process is assisted by
ER-resident chaperones, addition of N-linked glycans,
and formation of disulfide bonds (Helenius and Aebi,
2001). The high flux of proteins into the ER together with
the complicatedmultidomain nature ofmany secreted pro-
teins inevitably results in some fraction of proteins becom-
ing terminally misfolded (Casagrande et al., 2000; Fried-
lander et al., 2000; Jensen et al., 1995; Travers et al.,
2000; Ward et al., 1995). To protect cells from the deleteri-ouseffectsof such forms, theERemploysa seriesofmech-
anisms collectively referred to as ER-associated degrada-
tion (ERAD) to bring about their efficient disposal (Romisch,
2005). In most instances, substrates are first specifically
identifiedand then targeted forubiquitination inpreparation
for their destruction in the cytosol by the proteasome
(Meusser et al., 2005; Nishikawa et al., 2005; Romisch,
2005; Sayeed and Ng, 2005; Tsai et al., 2002). Depending
on the position of the misfolded lesion, the recognition
step can occur either on the luminal side (ERAD-L), the cy-
tosolic side (ERAD-C), or in the context of the ER mem-
brane itself (ERAD-M) (Bonifacino et al., 1990; Taxis et al.,
2003; Vashist and Ng, 2004). For luminal targets, Kar2p
(the major ER-localized Hsp70), has been shown to keep
substrates in an ERAD-competent soluble state (Kabani
et al., 2003; Nishikawa et al., 2001) and additionally partic-
ipates in a second, less well-defined step of bringing them
to the retrotranslocation machinery (Kabani et al., 2000),
which then delivers substrates across the membrane to
the cytosolically located catalytic sites of the ubiquitin con-
jugation machinery. Following ubiquitination by mem-
brane-associated ubiquitin ligases (e.g., Hrd1p and
Doa10p in yeast) (Bays et al., 2001; Deak and Wolf, 2001;
Swanson et al., 2001), substrates are typically extracted
from the membrane by the Ubx2p-recruited Cdc48p-
Npl4p-Ufd1p AAA ATPase (Jarosch et al., 2002; Neuber
et al., 2005; Schuberth and Buchberger, 2005; Ye et al.,
2001), which together with other ubiquitin binding proteins
escorts substrates to the proteasome (Richly et al., 2005).
Our understanding of the more downstream events in
ERAD is becoming increasingly sophisticated. By com-
parison, detailed information is lacking on how proteins
are initially selected for degradation and subsequently
delivered to the ubiquitination/extraction machinery. The
significance of understanding how the ER scans through
the abundance of folding intermediates for terminally
misfolded proteins is well illustrated by a recent study
showing that the most dangerous variants of an amyloido-
genic protein are those whosemutations are not so desta-
bilizing as to trigger detection by the ERAD system
(Sekijima et al., 2005). The complexity of the recognition
problem is further underscored by the risk of overvigi-
lance, which can lead to the degradation of imperfectCell 126, 349–359, July 28, 2006 ª2006 Elsevier Inc. 349
but potentially functional proteins, as appears to be the
case for the CFTR chloride channel (Drumm et al., 1991).
Degradation of ERAD-L substrates depends not just on
substrate misfolding but also on the presence of substrate
sugars (Kostova andWolf, 2005; Spear andNg, 2005). The
molecular basis of this dual requirement and how this in-
formation is communicated to the downstream ERADma-
chinery are unclear. Htm1p, a putative ER lectin required
for ERAD-L, may contribute to sugar recognition (Jakob
et al., 2001; Nakatsukasa et al., 2001). More recently,
Yos9p has been identified as a conserved ER lectin with
a critical role in the recognition of luminal misfolded glyco-
proteins (Bhamidipati et al., 2005; Buschhorn et al., 2004;
Kim et al., 2005; Szathmary et al., 2005). Furthermore, it
was shown that Yos9p can associate with the prototypical
ERAD-L substrate CPY* even when its sugar binding site
(critical for its ERAD function) is mutated and the substrate
is deglycosylated (Bhamidipati et al., 2005). This suggests
that Yos9p lies at the core of a poorly defined bipartite rec-
ognition machinery that specifically targets for retrotrans-
location only those proteins that are simultaneously mis-
folded and have the correct sugars.
Following recognition, ERAD-L substrates are delivered
to the cytosol, where they undergo ubiquitination by
Hrd1p (Bays et al., 2001; Deak andWolf, 2001). This mem-
brane bound ubiquitin ligase is associated stoichiometri-
cally with another key component of ERAD-L, Hrd3p,
whose presence is required to prevent Hrd1p from under-
going self-destruction (Gardner et al., 2000; Plemper
et al., 1999). The highly conserved, large (80 kDa) nature
of theHrd3p luminal region suggests that it may play an ad-
ditional role in early ERAD-L events. In fact, Hrd3p appears
to have a role other than stabilizing Hrd1p (Gardner et al.,
2000). Counteracting this view, however, is the finding
that simply restoring Hrd1p levels by overexpression sup-
presses the substrate degradation defect associated with
the lossofHrd3p (Gardneretal., 2000;Plemperetal., 1999).
In the present study we investigate themolecular mech-
anism by which ERAD-L substrates are recognized and
targeted for destruction. Specifically, we demonstrate
that Yos9p, Hrd3p, and Kar2p form a luminal surveillance
complex that recognizes misfolded substrates indepen-
dent of their glycosylation status and brings them to the
downstream ubiquitination/extraction machinery. Degra-
dation, however, requires a distinct commitment step
that is dependent on substrate sugars and Yos9p’s sugar
binding site. Finally, we show that in addition to its positive
role in enhancing recruitment of bona fide ERAD-L sub-
strates, the surveillance complex also helps eliminate
basal, indiscriminate degradation which otherwise leads
to cellular toxicity.
RESULTS
Yos9p Forms a Stable Complex with the
Transmembrane and Cytosolic ERAD Machinery
Previous studies have shown that Yos9p associates with
themisfolded, luminal ERAD substrate, CPY* (Bhamidipati350 Cell 126, 349–359, July 28, 2006 ª2006 Elsevier Inc.et al., 2005; Kim et al., 2005; Szathmary et al., 2005). This
recognition event is likely to occur in the context of amulti-
protein assembly as Yos9p is membrane associated but
does not itself contain a transmembrane domain (Fried-
mann et al., 2002; Kim et al., 2005). Furthermore, cross-
linking experiments suggested that substrate-associated
Yos9p was part of a discrete high molecular weight com-
plex (Bhamidipati et al., 2005). To gain insight into the
composition of this complex, we used an affinity purifica-
tion approach, taking advantage of a yeast strain express-
ing a functional 3xFLAG epitope-tagged version of Yos9p
expressed from its endogenous locus (Figure S1). Specif-
ically bound proteins were isolated from detergent-solubi-
lized microsomes and subjected to SDS-PAGE and Coo-
massie blue staining, thus identifying several abundantly
associated polypeptides. Mass spectrometry (Figure S2)
indicated that the Yos9p-specific bands consisted of the
following proteins: Cdc48p, Hrd3p, Kar2p, Yos9p/Ubx2p
(comigrating), Hrd1p, and Emp47p (Figure 1A). Addition-
ally, this complex contained Usa1p, a new ERAD compo-
nent identified and characterized in the accompanying
paper (Carvalho et al., 2006). Strikingly, with the exception
of Emp47p (the significance of whose association with
Yos9pwill be addressed elsewhere), all the Yos9p-associ-
ated proteins are known to be required for Yos9p-depen-
dent ER-associated degradation and include luminal
(Kar2p), transmembrane (Hrd1p, Hrd3p, Ubx2p, Usa1p),
and fully cytosolic (Cdc48p) ERAD components (Romisch,
2005). Thus, Yos9p is part of a stable complex that orga-
nizes a series of key components of ERAD machinery on
both sides of the ER membrane.
We performed further experiments to address two spe-
cific issues regarding the integrity of the complex. First,
two membrane proteins critical for ERAD-L, Der1p and
Htm1p (Jakob et al., 2001; Knop et al., 1996; Nakatsukasa
et al., 2001), were not identified in our affinity purification.
To exclude the possibility that these were integral compo-
nents of this membrane complex whose presence was
obscured for technical reasons, we repeated the purifica-
tion using strains deleted for der1 or htm1. These dele-
tions had no apparent effect on themolecular composition
of the Yos9p complex (Figures 2A and 2B). Second, we
wished to explore the role of Yos9p’s sugar binding
pocket in complex assembly. This was motivated by our
previous finding that point mutations specifically ablating
this region strongly eliminated Yos9p’s ability to support
ERAD-L but did not interfere with substrate interaction
(Bhamidipati et al., 2005). We therefore repeated the puri-
fication with a sugar binding mutant (R200A) but detected
no changes in the composition of the complex with the
apparent exception of a slight decrease in Coomassie
staining of the Yos9p/Ubx2p region (Figure 2C). However,
we demonstrated that the Yos9p/Ubx2p association was
not affected by directly monitoring levels of coimmuno-
precipitated Ubx2p using Western blotting (Figure 2D).
These data suggest that sugar recognition by Yos9p
acts at a step downstream of substrate binding and
complex assembly.
Figure 1. Yos9p Associates with the
Core ERAD Machinery at the ER Mem-
brane
Microsomes were prepared from late mid-log
phase cells expressing genomic copies of ei-
ther untagged Yos9p (A) or Yos9-FLAG (A–C)
in wild-type, Dhrd1, or Dhrd3 strain back-
grounds as shown. The microsomes were sol-
ubilized with Triton X-100 and affinity purified
using anti-FLAG beads. Immunoprecipitates
were eluted with 33FLAG peptide and re-
solved by SDS-PAGE followed by Coomassie
blue staining. The identity of bands in (A) was
determined by mass spectrometry. * denotes
the position of missing bands. Molecular
weights are labeled according to a prestained
protein ladder.
(D) As indicated, wild-type or kar2-1 cells were
transformed with empty vector or pRS315-
Yos9-FLAG. Prior to harvesting, cells were
shifted to the nonpermissive kar2-1 tempera-
ture (37C) for 1 hr. Subsequently, total cell
lysates were solubilized with 1% Triton X-100,
cleared, and immunoprecipitated with anti-
FLAG resin. Bound proteins were eluted by
boiling in SDS loading buffer and along with
total cell lysates were resolved by SDS-PAGE
followed by Western blot analysis with the
indicated antibodies.Yos9p/Kar2p/Hrd3p Form a Luminal Subcomplex
Since Yos9p is a strictly luminal protein, we wished to de-
termine the contribution of other members in the complex
to Yos9p’s ability to associate with Cdc48p on the cyto-
solic side. The multipass transmembrane protein Hrd1p
was a good candidate for allowing communication be-
tween the complex components on opposing sides of
the membrane (Deak and Wolf, 2001; Gardner et al.,
2000). Indeed, when we repeated the purification proce-
dure using a hrd1 deletion strain, we observed a complete
loss of Yos9p-associated Cdc48p (Figure 1B). In contrast,
Hrd3p association remained unaffected. Together with
IP-Western data confirming the presence of Hrd1p in the
Yos9p immunoprecipitations (Figure S3), this finding dem-
onstrated that despite its faint appearance by Coomassie
staining, Hrd1p is nonetheless absolutely required for
Cdc48p’s ability to associate in a complex with Yos9p.
The fact that Hrd3p has a large (80 kDa) luminal do-
main and exists in a 1:1 complex with the Hrd1p ubiquitin
ligase (Gardner et al., 2000) suggests that Hrd3p might be
responsible for anchoring Yos9p to Hrd1p/Cdc48p. In ac-
cordance with this idea, we observed a total absence of
Cdc48p when we purified Yos9p from a Dhrd3 strain (Fig-
ure 1C). Given that Kar2p and Yos9p closely migrate by
SDS-PAGE, we confirmed by Western blotting that the
Yos9p/Kar2p interaction is independent of the presence
of Hrd3p (Figure S4) and Cdc48p (Figure 1C). Additionally,we demonstrated that the Yos9p/Kar2p interaction is still
observed even when endogenous KAR2 has been re-
placed by the kar2-1 peptide binding mutant (Figure 1D)
(Kabani et al., 2003). This suggests that Kar2p’s associa-
tion with Yos9p is not solely mediated through Kar2p’s
ability to interact with unfolded proteins.
We further explored the Yos9p/Hrd3p interaction using
truncations of Hrd3p. Hrd3p comprises a luminal region,
consisting of domains A (residues 1–390) and B (residues
390–767), that is attached to a transmembrane anchor
and a cytosolic tail (residues 767–833) (Gardner et al.,
2000; Figure 3A). To investigate which of these regions
was responsible for the observed interaction with Yos9p,
we generated strains expressing from the endogenous
locus C-terminally tagged variants of Hrd3p and tested
their ability to coimmunoprecipitate Yos9p. As shown in
Figure 3B, both full-length and A-B (1–767) Hrd3p (but
not the A domain alone) were able to pull down Yos9p,
indicating that the B domain is required for Yos9p binding
while the transmembrane anchor and the cytosolic tail are
dispensable. We further find that strong overexpression of
either Yos9p or Hrd3p alone results in only a minor
enhancement in the amount of Hrd3p pulled down with
Yos9p (Figure 3C). However, concomitant overexpression
of both proteins resulted in a synergistic20-fold increase
in Yos9p/Hrd3p complex formation (Figure 3C). Moreover,
this interaction persisted even following deglycosylationCell 126, 349–359, July 28, 2006 ª2006 Elsevier Inc. 351
Figure 2. The Integrity of the Yos9p-Core
ERAD Machinery Complex Is Not Depen-
dent on Der1p, Htm1p, or Yos9p’s Sugar
Binding Pocket
Microsomesweremade fromwild-type,Dder1,
or Dhtm1 log phase cells expressing genomic
Yos9-FLAG (A and B) or Yos9-FLAG and
R200AYos9-FLAG from a plasmid (C) as indi-
cated. Microsomes were solubilized and
Yos9p was immunoprecipitated as described
in Figure 1A. Note: Usa1p comigrates with
Hrd3p. We did not explicitly test for the pres-
ence of Usa1p in the various deletion strains.
(D)Wild-type orUBX2-TAP::HISMX6 cells were
transformed with either an empty vector,
pRS315-Yos9-FLAG, or pRS315-R200AYos9-
FLAG as indicated and subjected to immuno-
precipitation as described in Figure 1D. Anti-
CBP was used to visualize the TAP fusion
protein while anti-Sec61p served as a negative
control.of both proteins by EndoH (Figure S5). Thus the observed
Yos9p interactionwithHrd3p is sugar independent andun-
likely to bebridgedbyother dedicatedERADcomponents.
Collectively, these findings lead us to propose the fol-
lowing model for the molecular organization of the com-
plex (Figure 3D). Yos9p, Kar2p, and the luminal domain
of Hrd3p form a complex, which is anchored to the trans-
membrane Hrd1p ubiquitin ligase (Gardner et al., 2000). In
turn, Hrd1p, in amanner that depends on its ligase activity,
recruits Ubx2p-tethered Cdc48p (Gauss et al., 2006; Neu-
ber et al., 2005; Schuberth and Buchberger, 2005), a cyto-
solic protein shown to be required for the extraction of
substrates from the ER membrane (Jarosch et al., 2002;
Ye et al., 2001). The transmembrane proteins Der1p and
Htm1p are central players in ERAD, but our results estab-
lish that they are not required for the integrity of the Yos9p
complex described here.
Yos9p and Hrd3p Can Recruit Misfolded Proteins
Independently of Each Other
We next wanted to explore how ERAD-L substrates are
recruited to the Hrd1p ubiquitin ligase complex. First we
tested whether the Yos9p-substrate interaction is depen-352 Cell 126, 349–359, July 28, 2006 ª2006 Elsevier Inc.dent on Hrd3p. As previously reported, Yos9p coimmuno-
precipitated with the prototypical ERAD-L substrate
CPY*, and this interaction did not depend on substrate
sugars, either alone or in combination with the R200A
Yos9p lectin mutant (Figures 4A and 4B), but was specific
for the misfolded form (Bhamidipati et al., 2005; Kim et al.,
2005; Szathmary et al., 2005; Figure S6). Importantly,
these interactions persisted even in strains lacking
HRD3, suggesting that they were being mediated directly
by Yos9p and/or Kar2p.
To investigate the simple model that Hrd3p is acting as
a passive scaffold for bridging the Yos9p/Kar2p/substrate
complexwith the downstreamERADmachinery, we asked
whether Yos9p was required for the ability of substrate to
be coimmunoprecipitated with Hrd3p (Gardner et al.,
2001; Gauss et al., 2006). We initially found that various
N- or C-terminally tagged versions of full-length Hrd3p ei-
ther gave veryweakWestern signals orwere nonfunctional
(data not shown). However, as demonstrated in the case of
HMG-CoAReductase 2degradation (Gardner et al., 2000),
Hrd31-767-MYC efficiently supported CPY* degradation
when tagged at the C terminus (Figure S7) and robustly in-
teracted with Yos9p (Figures 3B and 3C). As expected,
Figure 3. Dissection of the Yos9p/Hrd3p Interaction by Domain Mapping/Overexpression and a Model of How Yos9p Interacts
with Other Members of the ERAD Machinery
(A) Schematic of Hrd3p. Domain boundaries are demarcated with their amino acid position in the Hrd3p sequence. Tm denotes the transmembrane
domain.
(B) A 13MYC tag was inserted at the HRD3 locus following amino acids 390, 767, or 833 in a strain expressing Yos9 genomic FLAG. The cells were
immunoprecipitated with anti-MYC as described in Figure 1D.
(C) Strains expressing endogenous or overexpressed (symbolized with [ indicating TDH3 promoter driven expression) tagged versions of Yos9p and
Hrd31-767p were mated as shown and subjected to immunoprecipitation as described in Figure 1D. The numbers in parentheses indicate the levels of
each protein relative to the control strain expressing endogenous levels of both proteins.
(D) Proposed model of how Yos9p associates with other ERAD components in the ERmembrane and cytosol. Hrd1p anchors at least a portion of the
Yos9p/Kar2p/Hrd3p surveillance complex to the ER membrane and interacts with Ubx2p which recruits Cdc48p to the membrane complex (the
dependence of Cdc48p recruitment on Hrd1p’s ubiquitin ligase activity is not depicted in the figure). Der1p and Htm1p may associate but are not
important for the integrity of the complex. Ubc7p and its membrane anchor Cue1p are necessary for the ubiquitination of substrates by Hrd1p.
Usa1p not pictured.based on its association with Yos9p, Hrd3pwas able to in-
teract with both CPY* as well as with an unglycosylated
variant of CPY* (CPY*0000) that is not subject to ERAD-L
(Figure 5A) (Kostova and Wolf, 2005; Spear and Ng,2005). Surprisingly, we still observed coimmunoprecipita-
tion of Hrd3p with CPY* and CPY*0000 in a strain deleted
for YOS9 (Figure 5A). This interaction is likely to be direct
because it was observed even in the absence of Der1p,Cell 126, 349–359, July 28, 2006 ª2006 Elsevier Inc. 353
Htm1p, and Hrd1p (which is responsible for anchoring the
Hrd3p luminal domain) (Figures 5A and 5B). Furthermore,
we observed that overexpression of Hrd3p leads to a pro-
portional increase in the amount of Hrd3p-CPY* complex
recovered by immunoprecipitation (Figure 5C). Several
lines of evidence argue for the validity and specificity of
this interaction. First, the observed association between
Hrd3p and substrate is unlikely to be an artifact of inade-
quate membrane disruption as we solubilized lysates us-
ing a large excess of Triton X-100, a strong nonionic deter-
gent, andweobservedno interactionwith theabundantER
membrane protein Sec61p (Figures 5A and 5B). Second,
this interaction is not due to the formation of a large sub-
strate aggregate that nonspecifically incorporates other
proteins because it remains in the supernatant even after
clearing the solubilized lysates at 100,000 3 g for 45 min.
Finally, the interaction is highly specific for the misfolded
formof carboxypeptidase Y sincewe could vastly increase
the amount of native CPY in the ERby deleting the gene for
its ERexport receptor, Erv29p (BeldenandBarlowe, 2001),
without observing a significant interaction with Hrd3p (Fig-
ure 5D). We therefore conclude that Yos9p/Kar2p and
Hrd3p independently recognize misfolded ER luminal
proteins.
Figure 4. Yos9p interacts with CPY* and CPY*0000 in an
HRD3-Independent manner
(A) Dyos9Dder1HRD3 or Dyos9Dder1Dhrd3 cells were transformed
with pRS315-Yos9-FLAG, together with an empty vector, or one ex-
pressing CPY* or CPY*0000 as indicated. Following spheroplasting
and lysis by bead beating, crude membranes were solubilized with
1% Triton-X100 and subjected to immunoprecipitation with anti-HA
essentially as described in Figure 1D.
(B) Dyos9Dder1HRD3 or Dyos9Dder1Dhrd3 cells were transformed
with pRS315-R200AYos9-FLAG together with an empty vector or
a vector expressing CPY*0000, as indicated. Spheroplasting and im-
munoprecipitation were performed as described in Figure 4A.354 Cell 126, 349–359, July 28, 2006 ª2006 Elsevier Inc.Substrate Engagement with the Multiprotein Hrd1p
Ligase Complex Is Sugar Independent
The observation that the Yos9p lectin mutant (R200A) in-
teracted with both substrates (Figure 4) and downstream
ERAD components (Figure 2D) suggests that recognition
and commitment to degradation are mechanistically sep-
arable events. To test this idea further, we made use of
a recently identified ERAD-L component (Carvalho et al.,
2006), Usa1p. As expected based on Usa1p’s association
with Yos9p and Hrd3p (Carvalho et al., 2006; Figure S2),
we show that Usa1p can be coimmunoprecipitated with
CPY* in a Hrd3p-dependent manner (Figure 6). Notably,
despite the fact that CPY*0000 cannot be degraded by
the ERAD-L system, it nonetheless is part of a multiprotein
complex including Usa1p (Figure 6; Figure S8). These data
suggest that substrate recruitment to the ERAD core
machinery can be mechanistically distinguished from
a subsequent commitment to degradation. It is this
commitment step in the ERAD process that confers de-
pendence on substrate glycosylation and Yos9p’s sugar
binding site.
Hrd1p Gating by Yos9p/Hrd3p Prevents
Promiscuous Degradation
Our finding that Hrd3p plays a key role in bringing Yos9p to
the ubiquitin degradation machinery and independently
recognizing substrates seems at odds with previously
published reports indicating that the strong substrate deg-
radation defect in a Dhrd3mutant is bypassed by overex-
pression of Hrd1p (Gardner et al., 2000; Plemper et al.,
1999). To explore this apparent discrepancy, we first reca-
pitulated the phenomenon by placing Hrd1p under the
control of a strong (TDH3) promoter (Gardner et al.,
2000) and confirmed that CPY* stabilization in a hrd3 de-
lete is in fact partially alleviated by overexpression of
Hrd1p (Figure 7A). Next, we examined the contribution
of Yos9p to substrate recognition in the context of
Hrd1p overexpression and found that deleting YOS9 had
no effect on Hrd1p’s ability to stimulate CPY* degradation
(Figure 7A). This is in marked contrast to the strong CPY*
stabilizing effect of deleting YOS9 in strains with regulated
Hrd1p function (Bhamidipati et al., 2005; Buschhorn et al.,
2004; Kim et al., 2005; Szathmary et al., 2005; Figure S1).
In light of the above suggestion that the sugar binding site
of Yos9p acts at a commitment step that is downstream of
substrate recruitment to the complex, we wanted to rein-
vestigate the requirement for glycosylation in this Hrd1p
overexpression bypass regime. We first confirmed that
the removal of substrate sugars leads to a dramatic stabi-
lization of CPY*, comparable to that observed whenHRD3
or YOS9 are deleted. Strikingly, under conditions of Hrd1p
overexpression in a hrd3 deletion mutant, we saw signifi-
cant degradation of CPY*0000, such that its degradation
was now similar to that of CPY* (Figure 7B). This promis-
cuous destruction of an otherwise stable protein could ac-
count for our observation that overexpression of Hrd1p
causes S288C yeast strains to grow at a reduced rate (Fig-
ure 7C). In order to confirm that this effect was indeed due
Figure 5. Hrd3p Interacts Specifically with CPY* and CPY*0000 but Not Wild-Type CPY in a YOS9-Independent Manner
(A)Dder1YOS9HRD1, Dder1Dyos9HRD1, or Dder1Dyos9Dhrd1 cells expressing Hrd31-767-MYC were transformed with an empty vector or a vector
expressing CPY* or CPY*0000, as indicated, and subjected to immunoprecipitation as in Figure 1D.
(B) The indicated strains expressing Hrd31-767-MYC were transformed with an empty vector or a vector expressing CPY* or CPY*0000 as shown and
subjected to immunoprecipitation as in Figure 1D.
(C) Strains expressing endogenous or overexpressing tagged versions of Hrd31-767-MYC were transformed with empty vector or a vector expressing
CPY* and subjected to immunoprecipitation as in Figure 1D. Upward arrow indicates TDH3 promoter-driven expression.
(D)Dder1Derv29YOS9 orDder1Derv29Dyos9 cells expressing Hrd31-767-MYCwere transformedwith an empty vector or a vector expressing CPY* or
wild-type CPY, as indicated, and subjected to immunoprecipitation as described in Figure 1D.to deregulated ubiquitin ligase activity, we deleted CUE1,
the ER membrane anchor for the Ubc7p E2 enzyme (Bie-
derer et al., 1997), and observed suppression of both the
promiscuous degradation (Figures 7D and S9) and the
growth phenotype (Figure 7C). Taken together, thesedata suggest that uncensored Hrd1p activity caused by
the disruption of the Yos9p/Hrd3p gating mechanism re-
sults in the destruction of proteins normally spared by
the rules and restrictions of ERAD-L recognition, thus
leading to impaired cellular viability.Cell 126, 349–359, July 28, 2006 ª2006 Elsevier Inc. 355
DISCUSSION
The ERmust specifically identify terminally misfolded pro-
teins in an environment dominated by structurally similar
on-pathway folding intermediates. Compounding the
complexity of this substrate selection problem is the fact
Figure 6. Sugar-Independent Association of Misfolded Car-
boxypeptidase Y with Usa1p
Wild-type or Dhrd3 cells expressing C-terminally tagged Usa1-MYC
were transformed with an empty vector or a vector expressing CPY*
or CPY*0000, as indicated, and subjected to immunoprecipitation as
in Figure 1D.356 Cell 126, 349–359, July 28, 2006 ª2006 Elsevier Inc.that surveillance has to be enforced on three topological
fronts (luminal, membrane, and cytosolic). Accordingly,
the ER-associated degradation system comprises multi-
ple converging pathways (Romisch, 2005; Sayeed and
Ng, 2005). At the top of this arborized organization is
a multiplicity of recognition factors in charge of initiating
substrates down increasingly narrow paths that culminate
in their degradation by the cytosolic proteasome machin-
ery. While there have been substantial advances in under-
standing how in mammalian cells viruses target for de-
struction specific folded endogenous proteins such as
class I MHC heavy chains (Lilley and Ploegh, 2004,
2005; Ye et al., 2004, 2005), it remains poorly understood
how recognition of terminally misfolded proteins is ac-
complished and coupled to shared downstream ERAD
components.
In the present study we address this substrate selectiv-
ity issue for ERAD-L, a major conserved pathway respon-
sible for the degradation of luminal misfolded glycopro-
teins (Vashist and Ng, 2004). In order to focus on a
single, coherent branch of the ERAD system, we started
with a top-down approach centered on Yos9p, a luminal
lectin thought to act early in the pathway. This led to the
identification of a Yos9p/Kar2p/Hrd3p surveillance com-
plex that brings ERAD-L substrates into contact with the
downstream Hrd1p ubiquitin ligase and the accompany-
ing Ubx2p-recruited Cdc48p. Remarkably, both Yos9p/
Kar2p and Hrd3p can individually recognize theFigure 7. Overexpression of Hrd1p in a
Dhrd3 Background Results in Increased
Degradation of CPY* and CPY*0000 in
a YOS9-Independent Manner
(A) Degradation of CPY* in (A) wild-type (WT),
(,) Dhrd3[HRD1 (upward arrow indicates
TDH3 promoter-driven expression), (D)
Dhrd3Dyos9[HRD1, and (d) Dhrd3 back-
grounds was monitored by the cyloheximide
chase degradation assay. Equal amounts of
cells were removed at the indicated time points
following addition of cycloheximide and sub-
jected to SDS-PAGE followed by Western blot-
ting with anti-HA and anti-hexokinase anti-
bodies. Each time point represents the average
and standard deviation of four measurements
(two independent experiments done in dupli-
cate) normalized to a loading control.
(B) Degradation of CPY* in (A) wild-type (WT),
(,) Dhrd3[HRD1 (upward arrow indicates
TDH3 promoter-driven expression) cells or
CPY*0000 in (d) wild-type, (D) Dhrd3[HRD1
cells was monitored as in Figure 7A.
(C) Dcue1 and Dhrd3[HRD1 were crossed and
sporulated.Wild-type (WT),Dhrd3,Dhrd3[HRD1
(upward arrow indicates TDH3 promoter-driven
expression), and Dcue1Dhrd3[HRD1 cells were
grown on minimal media lacking tryptophan.
(D) Degradation of CPY* in (A) wild-type (WT) or
CPY*0000 in (d) wild-type, (,) Dhrd3[HRD1
(upward arrow indicates TDH3 promoter-driven
expression), or (D) Dcue1Dhrd3[HRD1 cells
was monitored as in Figure 7A.
prototypical ERAD-L substrate CPY* in a manner that de-
pends on the folding status but not the glycosylation state
of the substrate. The above recruitment step tethers puta-
tive substrates to the ubiquitination/extraction machinery
on the other side of the membrane by way of the Hrd3p/
Hrd1p interaction. Substrate degradation requires a dis-
tinct commitment step that is dependent on both the sub-
strate sugars and an intact Yos9p sugar binding site. The
mechanism by which this commitment step allows sub-
strates to proceed down the ERAD-L pathway remains un-
clear. One intriguing possibility is that Yos9p, possibly to-
gether with Htm1p, queries the sugar status of the
substrate and, for glycoproteins judged to be legitimate
ERAD substrates, allows for the participation of Der1p in
the subsequent retrotranslocation step. Interestingly, re-
cent studies suggest physical interaction between glyco-
sylated ERAD substrates and Der1p/Derlin (Gauss et al.,
2006; Oda et al., 2006), arguing for the possible existence
of distinct substrate recognition events that are not medi-
ated by the Yos9p/Hrd3p recruitment complex. It remains
to be established how this multiplicity of recognition
events are coordinated to bring about the substrate com-
mitment to degradation.
Why has such a baroque mechanism evolved for selec-
tion of ERAD substrates? While the exact structural and
kinetic features of misfolded proteins that lead to their
recognition by the ERADmachinery are not well delineated,
it now appears that recognition does not simply involve
assessmentof aprotein’s thermodynamicstability (Sekijima
et al., 2005). The cooperation of two interacting complexes
(Hrd3p and Yos9p/Kar2p), each of which are individually
capable of binding misfolded forms, could allow for a
more sophisticated probing of the biophysical properties
of nonnative proteins. For example, dual binding would be
expected to favor recognition of substrates with extended
or multiple nonnative epitopes. On a more speculative
note, the use of a two-step process (i.e., recruitment and
commitment) could allow for enhanced specificity by a ki-
netic proofreading mechanism, especially if the two steps
are separated by an irreversible process (Hopfield, 1974)
such as, for example, sugar trimming (Hirao et al., 2006) or
ATP hydrolysis by Kar2p. Additionally, there may be proof-
reading steps upstream and/or downstream of the Yos9p/
Hrd3p recruitment process studied here.
More concretely, we demonstrate that the Yos9p/
Kar2p/Hrd3p surveillance complex promotes specificity
by acting as a gatekeeper of theHrd1p ubiquitin ligase, en-
suring that only legitimate substrates are degraded. It acts
to enhance the delivery and degradation of bona fide
ERAD-L substrates while on the other hand repressing in-
discriminate degradation of ER proteins. The significance
of suppressing the basal degradation activity is illustrated
by the slow growth phenotype that results when upstream
recognition is bypassed in a hrd3 deletion mutant overex-
pressing Hrd1p. Such deleterious effects are elegantly
avoided in wild-type cells by the fact that Hrd1p has a built
in autodestruction mechanism when it is not complexed
with Hrd3p (Gardner et al., 2000; Plemper et al., 1999).This reduced specificity for retrotranslocation caused by
Hrd1p overexpression is reminiscent of bacterial trans-
locon mutants that are able to promiscuously export
polypeptides in a signal sequence-independent manner
(Flower et al., 1994).
More practically, manipulating the specificity of the
ERAD system could yield an attractive therapeutic strat-
egy (e.g., for supporting degradation of a mutant allele).
However, such efforts are hampered by the broad protec-
tive role of the ERAD systems and the fact that many
ERAD components are shared with other biological pro-
cesses (Adams, 2002). Because the ERAD-L surveillance
complex is dedicated to channeling only a subset of
ERAD substrates for degradation, a better understanding
of this targeting step may aid in the development of future
pharmacological approaches with enhanced selectivity
for specific disease processes.
EXPERIMENTAL PROCEDURES
Plasmid and Strain Construction
See Supplemental Experimental Procedures.
Antibodies
Sec61p and Kar2p antisera were a gift from Randy Schekman (Univer-
sity of California, Berkeley) and Peter Walter (University of California,
San Francisco). HA epitope was detected using 12CA5 monoclonal
antibody (Roche). In Figure 4B, HA epitope was detected using poly-
clonal Y11 HA-probe (Santa Cruz Biotechnology). Anti-CBP TEV-N
Peptide, anti-FLAG M2 monoclonal antibody, anti-hexokinase, and
anti-CPY mouse monoclonal 10A5 were purchased from Bethyl
Laboratories Inc, Sigma, US Biologicals, and Molecular Probes, Inc,
respectively. MYC tag was detected by 9E10 monoclonal antibody
(Roche). Secondary Antibodies labeled with IR800 dye and Alexa Fluor
680 were purchased from Rockland Immunochemicals and Molecular
Probes, Inc, respectively.
Native Immunoprecipitations—Large Scale
ER derived microsomes were prepared from late mid-log phase yeast
cells (2800 OD600 units) grown in YPD (The strains in Figure 2C were
grown in selective media) and harvested by centrifugation. The cells
were washed with water, resuspended in 50 ml of 100 mM Tris-HCL
[9.4] buffer containing 10 mm DTT, and incubated for 5 min at room
temperature. The cells were pelleted and resuspended in 20 ml
lyticase buffer (50 mM Tris-HCL [7.8], 1 M sorbitol, 5 mM bMe, 100
mM NaCl). Three milliliters of lyticase made using a plasmid that was
a gift from Randy Schekman (University of California, Berkeley) was
added and the cells were incubated at 30 degrees until at least 80%
spheroplasting efficiency was achieved. The spheroplasts were pel-
leted at 3000 g for 4 min at 4C and washed with lyticase buffer before
being resuspended in 25 ml of cold lysis buffer (25 mM HEPES-KOH
[6.8], 10 mM NaCl, 200 mM sorbitol, 1 mMMgCl2, 1 mM CaCl2, prote-
ase inhibitors). The cells were then incubated for 15 min on ice and
lysed by douncing. The lysates were cleared twice at 1000 g for 8
min and the resulting supernatant was subjected to a high-speed
spin at 50,000 g. The microsome pellet was washed once before being
solubilized in 5 ml HEPES IP buffer (50 mMHEPES-KOH [6.8], 150 mM
KOAc, 2 mMMgOAc, 1 mM CaCl2, protease inhibitors) plus 1% Triton
X-100 for 1 hr at 4C. The solubilizedmicrosomeswere spun for 22min
at 50,000 g. One hundred and twenty to one hundred and fifty micro-
liters pre-equilibrated anti-FLAG resin (Sigma) was added to the super-
natant and incubated at 4C for 3 hr. The immunoprecipates were
washed with 4 3 5 ml of IP buffer plus 1% Triton X-100. The bound
protein was eluted with 60–75 ul of 33 FLAG peptide (Sigma)Cell 126, 349–359, July 28, 2006 ª2006 Elsevier Inc. 357
resuspended in IP buffer plus 1% Triton X-100 to a final concentration
of 1mg/ml andmixing on ice for 30min. SDS loading buffer was added
to half of the eluate and run on 4%–12% SDS-PAGE gels followed by
staining overnight with Colloidal Blue stain (Invitrogen), referred to as
Coomassie blue in the text.
For Figure 1A, protein bandswere excised from the gel and analyzed
by Arnie Falick, David King, and Sharleen Zhou at the Howard Hughes
Medical Institute Mass Spectrometry Laboratory, University of Califor-
nia, Berkeley. Gel slices were trypsinized (Promega) and mass spectra
were acquired on a Bruker Reflex III MALDI-TOF mass spectrometer.
Proteins were identified by searching NCBInr database using MS-Fit
program on Protein Prospector (UCSF, http://prospector.ucsf.edu)
(Jimenez et al., 1998).
Native Immunoprecitations—Small Scale
Yeast cells (40–80 OD600 units depending on experiment) were grown
to late mid-log phase in selective media. After being washed in water,
cells were lysed by bead beating in 0.5 ml HEPES IP buffer containing
0.1%Triton X-100. The detergent concentration was then raised to 1%
in a final volume of 1 ml. The crude lysate was solubilized for 30 min at
4C and then spun at 100,000 g for 45min (except for Figure 3B, which
was done at 21,000 g for 10 min). The cleared supernatant was added
to 25 ml of equilibrated affinity resin and incubated at 4C for 1–3 hr.
The immunoprecipitates were washed 4 3 1 ml with HEPES IP buffer
plus 1% Triton X-100. Bound material was eluted by boiling in SDS
loading buffer and subjected to SDS-PAGE followed by Western
blotting and detection using the LI-COR Odyssey system.
An alternative lysis protocol was used for Figures 4A, 4B, and S6.
Here the cells were first spheroplasted (Bhamidipati et al., 2005) before
being lysed by bead beating in HEPES IP buffer containing 0.2 M
sorbitol (without detergent). The lysate was spun at 21,000 g for 10
min and the resulting crude membrane fraction solubilized in 1 ml of
HEPES IP buffer plus 1% Triton X-100 for 30 min at 4C. The resulting
solubilized membranes were cleared and processed exactly as indi-
cated above.
EndoH treatment was performed as described (Bhamidipati et al.,
2005).
Cycloheximide Chase Degradation Assay
Cycloheximide chase degradation assays were performed as previ-
ously described (Bhamidipati et al., 2005). In brief, log phase cells
were treatedwith 200mg/ml cycloheximide to terminate protein synthe-
sis. Time points were aliquoted into cold YEP (to facilitate subsequent
pelleting) and 10mMNaF/NaN3 followedby pelleting and flash freezing
in liquid nitrogen. The cells were then lysed with boiling SDS loading
buffer, subjected to SDS-PAGE, and immunoblotted as described
above. Bands were visualized using the LI-COR Odyssey system
(which allows for two color detection) and subsequently quantitated
with LI-COR Odyssey software. Following normalization to the hexoki-
nase loading control, the values were plotted as averages ± standard
deviation of four measurements (two independent experiments done
in duplicate) with time point 0 set to 100%.
Supplemental Data
Supplemental Data include nine figures and experimental procedures
and can be found with this article online at http://www.cell.com/cgi/
content/full/126/2/349/DC1/.
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